HIV suppression with stavudine 30 mg versus 40 mg in adults over 60 kg on antiretroviral therapy in South Africa

Christopher J. Hoffmann, Salome Charalambous, Katherine L. Fielding, Craig Innes, Richard E. Chaisson, Alison D. Grant, Gavin J. Churchyard

Research output: Contribution to journalArticle

Abstract

In 2007, the WHO recommended a maximum stavudine dose of 30 mg. We compared virologic suppression among patients weighing more than 60 kg and receiving stavudine 30 mg (n = 110) versus 40 mg (n = 508) in community HIV clinics in South Africa, before and after guidelines changed. At 6 months, HIV RNA less than 400 copies/ml was achieved in 79% and 81% receiving 30 and 40 mg stavudine, respectively (χ, P = 0.6). In regression modeling, including baseline HIV RNA and nonnucleoside reverse transcriptase inhibitor agent, stavudine dose remained unassociated with suppression.

Original languageEnglish (US)
Pages (from-to)1784-1786
Number of pages3
JournalAIDS
Volume23
Issue number13
DOIs
StatePublished - Aug 24 2009

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'HIV suppression with stavudine 30 mg versus 40 mg in adults over 60 kg on antiretroviral therapy in South Africa'. Together they form a unique fingerprint.

  • Cite this